Genitsaridi, I., Flouri, I., Plexousakis, D., Marias, K., Boki, K., Skopouli, F., . . . Sidiropoulos, P. (2020). Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group. Arthritis Res Ther.
Citação norma ChicagoGenitsaridi, Irini, et al. "Rheumatoid Arthritis Patients On Persistent Moderate Disease Activity On Biologics Have Adverse 5-year Outcome Compared to Persistent Low-remission Status and Represent a Heterogeneous Group." Arthritis Res Ther 2020.
Citação norma MLAGenitsaridi, Irini, et al. "Rheumatoid Arthritis Patients On Persistent Moderate Disease Activity On Biologics Have Adverse 5-year Outcome Compared to Persistent Low-remission Status and Represent a Heterogeneous Group." Arthritis Res Ther 2020.